Article

B&L to join with German-based refractive surgery business

Bausch & Lomb (B&L) is joining a German laser surgery equipment developer to create a new refractive surgery business.

Rochester, NY

-Bausch & Lomb (B&L) is joining a German laser surgery equipment developer to create a new refractive surgery business.

"We believe that our investment of assets in the joint venture will help advance the refractive industry, benefiting ophthalmologists and patients worldwide," said Gerald M. Ostrov, chairman and chief executive officer, B&L. "20/10 Perfect Vision's development of presbyopia-correcting treatments using its Femtec femtosecond laser-when paired with our proven refractive products, R&D insights, and global sales and marketing resources-holds tremendous potential to stimulate growth in corneal refractive surgery."

 "We are excited about this unique opportunity to form a global company committed to focusing on refractive laser surgery," said Dr. Kristian Hohla, executive president of 20/10 Perfect Vision. "Combining innovative teams, visionary technologies, and state-of-the-art refractive surgery products will yield a powerful portfolio of options for customers and patients."

B&L will have a large investment stake in the venture, which will include 20/10 Perfect Vision AG's technology and B&L refractive surgery products and sales and marketing operations.

The new company, which has not yet been named, will be based in Germany including about 20 of B&L's 1,600 local workers. The new joint venture is scheduled to be complete by the end of the year.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times)  ASCRS 2025: Joaquin De Rojas, MD, leverages machine learning model to predict arcuate outcomes
(Image credit: Ophthalmology Times) ASCRS 2025: AnnMarie Hipsley, DPT, PhD, presents VESA for biomechanical simulation of presbyopia progression
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
© 2025 MJH Life Sciences

All rights reserved.